Rigel Pharmaceuticals Inc. [NASDAQ: RIGL] surged by $0.02 during the normal trading session on Friday and reaching a high of $4.05 during the day while it closed the day at $3.99. The company report on March 11, 2021 that Rigel Announces Completion of Patient Enrollment for NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients.
Topline data expected in April 2021.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced the completion of patient enrollment in a multi-center Phase 2 clinical trial to evaluate the safety of fostamatinib, Rigel’s oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients. The study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), in collaboration with Inova Health System. Fostamatinib is marketed in the U.S. as TAVALISSE® (fostamatinib disodium hexahydrate) tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP).
Rigel Pharmaceuticals Inc. stock has also loss -5.67% of its value over the past 7 days. However, RIGL stock has inclined by 7.55% in the 3 months of the year. Over the past six months meanwhile, it has gained 53.46% and gained 14.00% year-on date.
The market cap for RIGL stock reached $675.91 million, with 169.04 million shares outstanding and 168.46 million shares in the current float. Compared to the average trading volume of 3.76M shares, RIGL reached a trading volume of 6877817 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Rigel Pharmaceuticals Inc. [RIGL]:
JP Morgan have made an estimate for Rigel Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 09, 2020. While these analysts kept the previous recommendation, Cantor Fitzgerald dropped their target price from $7 to $5. The new note on the price target was released on November 15, 2019, representing the official price target for Rigel Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $7, while JP Morgan analysts kept a Overweight rating on RIGL stock. On March 01, 2019, analysts decreased their price target for RIGL shares from 9 to 7.
The Average True Range (ATR) for Rigel Pharmaceuticals Inc. is set at 0.31, with the Price to Sales ratio for RIGL stock in the period of the last 12 months amounting to 6.22. The Price to Book ratio for the last quarter was 19.95, with the Price to Cash per share for the same quarter was set at 0.34.
RIGL stock trade performance evaluation
Rigel Pharmaceuticals Inc. [RIGL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.67. With this latest performance, RIGL shares dropped by -16.18% in over the last four-week period, additionally plugging by 53.46% over the last 6 months – not to mention a rise of 182.98% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RIGL stock in for the last two-week period is set at 47.46, with the RSI for the last a single of trading hit 45.76, and the three-weeks RSI is set at 49.08 for Rigel Pharmaceuticals Inc. [RIGL]. The present Moving Average for the last 50 days of trading for this stock 4.05, while it was recorded at 4.07 for the last single week of trading, and 2.96 for the last 200 days.
Rigel Pharmaceuticals Inc. [RIGL]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Rigel Pharmaceuticals Inc. [RIGL] shares currently have an operating margin of -26.67 and a Gross Margin at +99.18. Rigel Pharmaceuticals Inc.’s Net Margin is presently recorded at -27.38.
Return on Total Capital for RIGL is now -35.50, given the latest momentum, and Return on Invested Capital for the company is -40.37. Return on Equity for this stock declined to -67.72, with Return on Assets sitting at -23.06. When it comes to the capital structure of this company, Rigel Pharmaceuticals Inc. [RIGL] has a Total Debt to Total Equity ratio set at 114.87. Additionally, RIGL Total Debt to Total Capital is recorded at 53.46, with Total Debt to Total Assets ending up at 35.41. Long-Term Debt to Equity for the company is recorded at 89.54, with the Long-Term Debt to Total Capital now at 41.67.
Reflecting on the efficiency of the workforce at the company, Rigel Pharmaceuticals Inc. [RIGL] managed to generate an average of -$176,000 per employee. Receivables Turnover for the company is 8.33 with a Total Asset Turnover recorded at a value of 0.84.Rigel Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.10 and a Current Ratio set at 2.20.
Earnings per share (EPS) analysis for Rigel Pharmaceuticals Inc. [RIGL] stock
With the latest financial reports released by the company, Rigel Pharmaceuticals Inc. posted 0.13/share EPS, while the average EPS was predicted by analysts to be reported at 0.13/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RIGL.
Rigel Pharmaceuticals Inc. [RIGL]: Insider Ownership positions
There are presently around $558 million, or 84.80% of RIGL stock, in the hands of institutional investors. The top three institutional holders of RIGL stocks are: FMR LLC with ownership of 20,913,103, which is approximately -1.388% of the company’s market cap and around 0.31% of the total institutional ownership; BLACKROCK INC., holding 17,493,420 shares of the stock with an approximate value of $69.8 million in RIGL stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $44.68 million in RIGL stock with ownership of nearly -18.378% of the company’s market capitalization.
Positions in Rigel Pharmaceuticals Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 68 institutional holders increased their position in Rigel Pharmaceuticals Inc. [NASDAQ:RIGL] by around 12,235,458 shares. Additionally, 68 investors decreased positions by around 12,619,147 shares, while 28 investors held positions by with 115,101,843 shares. The mentioned changes placed institutional holdings at 139,956,448 shares, according to the latest SEC report filing. RIGL stock had 26 new institutional investments in for a total of 4,760,999 shares, while 15 institutional investors sold positions of 1,202,344 shares during the same period.